Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Sun Pharma

Pharmaceutical intelligence for Sun Pharma with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
3
Assets
5

Recent signals(3)

RegulatoryJune 20, 2026

FDA Accepts ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate by Sun Pharma

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Dextromethorphan Hydrobromide and Quinidine Sulfate submitted by Sun Pharma.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for Absorica by Sun Pharma

The FDA has accepted a supplemental application for Absorica, an isotretinoin product from Sun Pharma.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(3)

RegulatoryJune 20, 2026

FDA Accepts ANDA for Dextromethorphan Hydrobromide and Quinidine Sulfate by Sun Pharma

The FDA has accepted the Abbreviated New Drug Application (ANDA) for Dextromethorphan Hydrobromide and Quinidine Sulfate submitted by Sun Pharma.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for Absorica by Sun Pharma

The FDA has accepted a supplemental application for Absorica, an isotretinoin product from Sun Pharma.

RegulatoryJune 18, 2026

FDA Accepts Supplement for ABSORICA LD by Sun Pharma

The FDA has accepted a supplemental application for ABSORICA LD, an isotretinoin product by Sun Pharma.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

Absorica →
ABSORICA LD →
Dermatology →
FDA →
Regulatory Approval →

Therapeutic areas

Acne →
Cough Suppressant →
Dermatology →
Dermatology · Acne →
Neurology →
Neurology · Cough Suppressant →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.